**Core Concept**
The question is testing the concept of **allosteric modulation**, where a drug binds to a receptor at a site other than the active site, affecting the receptor's ability to bind to its endogenous ligand. This is a key concept in **pharmacodynamics**, the study of the biochemical and physiological effects of drugs. The receptor's affinity for its ligand is a crucial aspect of its function.

**Why the Correct Answer is Right**
An **allosteric antagonist** binds to a distinct site on the receptor, reducing the receptor's affinity for the endogenous ligand. This is achieved through a conformational change in the receptor, which decreases its ability to bind to the ligand. The binding of the allosteric antagonist to its site is **non-competitive**, meaning it does not compete with the endogenous ligand for the active site.

**Why Each Wrong Option is Incorrect**
**Option A:** An **agonist** would increase the receptor's activity, not reduce its affinity for the ligand.
**Option B:** An **inverse agonist** would decrease the receptor's activity, but it would not necessarily reduce the affinity for the endogenous ligand.
**Option C:** A **competitive antagonist** would compete with the endogenous ligand for the active site, not bind to a distinct site.

**Clinical Pearl / High-Yield Fact**
Allosteric modulation is a key mechanism of action for many drugs, allowing for more specific and targeted therapies. Understanding allosteric modulation is crucial for **rational drug design** and **pharmacotherapy**.

**Correct Answer:** D. Allosteric antagonist.